Camp4 Therapeutics Files 8-K

Ticker: CAMP · Form: 8-K · Filed: May 16, 2025 · CIK: 1736730

Sentiment: neutral

Topics: sec-filing, 8-k

TL;DR

Camp4 Therapeutics filed a routine 8-K on 5/16/25. No major news.

AI Summary

Camp4 Therapeutics Corp. filed an 8-K on May 16, 2025, to report current information. The filing does not disclose specific material events, financial statements, or exhibits that would typically require a detailed summary. It serves as a standard notification to the SEC.

Why It Matters

This filing indicates Camp4 Therapeutics Corp. is making a required disclosure to the SEC, which is standard for public companies but doesn't reveal specific business developments.

Risk Assessment

Risk Level: low — This is a routine filing with no new material information disclosed, thus posing minimal risk.

Key Players & Entities

FAQ

What is the purpose of this 8-K filing by Camp4 Therapeutics Corp.?

The filing is a Current Report on Form 8-K, used to announce material events that occur between the regular filings of annual and quarterly reports. This specific filing does not detail any particular event, suggesting it may be for routine disclosures or to satisfy regulatory requirements.

When was this 8-K filed with the SEC?

The 8-K filing was made on May 16, 2025.

Where is Camp4 Therapeutics Corp. headquartered?

Camp4 Therapeutics Corp.'s principal executive offices are located at One Kendall Square, Building 1400 West, 3rd Floor, Cambridge, MA 02139.

Under which section of the Securities Exchange Act is this report filed?

This Form 8-K is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

What is the SIC code for Camp4 Therapeutics Corp.?

The Standard Industrial Classification (SIC) code for Camp4 Therapeutics Corp. is 2834, which corresponds to Pharmaceutical Preparations.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on May 16, 2025 regarding Camp4 Therapeutics Corp (CAMP).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing